Zeto Showcases FDA-Cleared EEG Solutions and AI Reporting at Neurology Conference

According to a recent LinkedIn post from Zeto Inc, the company is showcasing multiple EEG solutions on the final day of the American Academy of Neurology Annual Meeting 2026. The post highlights live demonstrations at booth #1424, featuring Zeto ONE for hospitals, the newly FDA-cleared New Wave system for clinics, and the NeuroNotis AI-powered seizure detection report.

The post suggests that Zeto is targeting both inpatient and outpatient neurology settings, which may broaden its addressable market across hospital and clinic customer segments. The FDA clearance of New Wave, together with an AI-enhanced reporting workflow, could support stronger competitive differentiation and may help drive future adoption and recurring software or service revenue.

By emphasizing live demos and hands-on evaluations at a major neurology conference, Zeto appears to be focusing on clinician engagement and validation of its technology in real-world workflows. For investors, visible activity at AAN 2026 may indicate an active commercial push and could be an early signal of sales pipeline development, though no specific financial metrics or guidance are mentioned in the post.